Clinical Trials
12 trialsNCT02592317 2026-05-08
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT04597411 2026-04-30
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Active not recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06242470 2026-02-05
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Recruiting
NCT06067841 2026-02-04
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 1 Recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT05743621 2025-11-21
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed